Costs & Hospitals For Neoadjuvant Therapy in India

Neoadjuvant therapy in India is an adjunctive therapy given before the main therapy, and has become an integral part of modern multidisciplinary cancer management. Organised by the primary organ involved by cancer, this review summarises the outcomes of neoadjuvant therapy for common malignant solid tumours, based on large, randomised, controlled trials.

Book Appointment

Get a free quote

In locally advanced bladder and cervical cancer, patients who undergo neoadjuvant therapy before radical surgery appear to have better survival than those receiving definitive therapy alone; however, it is unclear if the neoadjuvant approach will be superior to definitive therapy followed by adjuvant therapy.

What is Neoadjuvant Therapy?

Neoadjuvant therapy is treatment given before the main treatment, usually surgery, to shrink a tumour and improve the chances of a successful outcome. It can include chemotherapy, radiation, hormone therapy, or targeted treatments. This approach helps make tumours easier to remove, may allow less invasive surgery, and can also begin treating cancer that may have spread. Commonly used in breast, rectal, lung, and oesophageal cancers, neoadjuvant therapy also helps doctors assess how well the cancer responds to the treatment.

The main purpose of the Neoadjuvant therapy in India is:

Reduce the tumour size before surgery or radiation.
Improve surgical outcomes, possibly allowing less invasive procedures.
Treat micrometastases (tiny cancer spreads not yet visible on scans).
Assess tumour response to therapy early on.

All Details About Application of Neoadjuvant Therapy in India

It enables patients with locally advanced laryngeal cancer to have their vocal function preserved. Many patients with rectal cancer can avoid permanent colostomy after undergoing this approach. In addition, in certain cancers, neoadjuvant therapy may improve long-term survival. Recent years have seen an increase in the popularity of this treatment technique. The number of clinical trials on this topic published from 2000 to 2003 exceeded the number published during the entire previous decade.

This review summarises the outcomes of neoadjuvant therapy for common malignant solid tumours. Since many patients rely on non-oncologists for guidance and support during cancer treatment, understanding the rationale and benefit of neoadjuvant therapy may aid primary care physicians in providing support and encouragement to their patients, ultimately improving care and treatment outcomes. The effect of neoadjuvant therapy can be delineated by comparing it with main therapy alone, or in some cancers, with main therapy plus adjuvant therapy, an adjunctive therapy given after the main treatment modality. This review, organised by organ of primary cancer, puts emphasis on long-term survival and organ preservation based on large phase III randomised, controlled trials.

Neoadjuvant Therapy for Breast Cancer

Neoadjuvant therapy for breast cancer is given before surgery to shrink the tumour and make it easier to remove. It often includes chemotherapy, hormone therapy, or targeted drugs, depending on the cancer type. This approach can help preserve breast tissue, allowing for breast-conserving surgery instead of mastectomy. It also helps assess how well the cancer responds to treatment, guiding further care. Neoadjuvant therapy is especially useful in aggressive or large tumours, triple-negative, or HER2-positive breast cancers.

Neoadjuvant Therapy for Rectal Cancer

Neoadjuvant therapy for rectal cancer is typically a combination of chemotherapy and radiation given before surgery. Its main goal is to shrink the tumour, reduce local spread, and improve the chances of complete surgical removal. This approach also lowers the risk of cancer coming back in the pelvic area. In some cases, it may even allow for less invasive surgery or preserve bowel function. Neoadjuvant therapy is especially beneficial in locally advanced rectal cancers to improve long-term outcomes and survival.

Neoadjuvant Therapy in Bladder Cancer

Neoadjuvant therapy in bladder cancer involves giving chemotherapy before surgery, usually before a radical cystectomy. It helps shrink the tumour, kill hidden cancer cells, and improve survival rates. This approach is especially effective in muscle-invasive bladder cancer, where the disease has spread into the bladder wall. By starting treatment early, doctors can better assess the cancer’s response and plan further care. Studies show that neoadjuvant chemotherapy can increase the chances of a complete pathological response and reduce the risk of recurrence.

Neoadjuvant Therapy Examples

Neoadjuvant therapy is widely used in cancer treatment to shrink tumours before surgery. A well-known example is breast cancer. In a case at Tata Memorial Hospital, a 42-year-old woman with HER2-positive locally advanced breast cancer received neoadjuvant chemotherapy with trastuzumab. Her tumour size reduced significantly, enabling breast-conserving surgery instead of mastectomy. Post-surgery analysis showed a complete pathological response, improving her prognosis.

In rectal cancer, a 55-year-old male patient at AIIMS, Delhi, was diagnosed with stage III rectal cancer. He received neoadjuvant chemoradiotherapy for six weeks, which led to a 60% reduction in tumour size. The surgery that followed was less extensive, and the patient retained bowel function, avoiding a permanent colostomy.

Book Appointment

Get a free quote

In bladder cancer, a 60-year-old man with muscle-invasive disease was treated at PGI Chandigarh. He underwent neoadjuvant chemotherapy with cisplatin-based drugs before cystectomy. The tumour responded well, and pathology showed minimal residual disease, increasing his survival chances.

These examples highlight how neoadjuvant therapy not only improves surgical outcomes but also helps tailor further treatment. It is particularly useful in aggressive or advanced tumours, offering a better quality of life and survival rates for patients.

Neoadjuvant Vs. Adjuvant- Neoadjuvant Therapy in India

Neoadjuvant therapy is given before the main treatment (usually surgery) to shrink the tumour and improve surgical outcomes. Adjuvant therapy is given after the main treatment to eliminate any remaining cancer cells and reduce the risk of recurrence.

Neoadjuvant Vs. Adjuvant- Neoadjuvant Therapy in India

Feature	Neoadjuvant Therapy	Adjuvant Therapy
Timing	Before surgery or main treatment	After surgery or main treatment
Purpose	Shrink the tumour, make surgery easier	Kill remaining cancer cells, prevent recurrence
Common Use Cases	Breast, rectal, lung, and bladder cancers	Breast, colon, ovarian, and many other cancers
Treatment Types	Chemotherapy, radiation, hormone or targeted therapy	Same as neoadjuvant
Tumour Response Check	Helps assess tumour sensitivity to treatment	No immediate way to assess response
Impact on Surgery	May allow less extensive surgery	No effect on surgery since it follows it
Goal	Downstage tumour improves the surgical outcome	Improve long-term survival and reduce recurrence

Neoadjuvant Therapy Procedure & Details

Neoadjuvant therapy involves a structured, step-by-step approach before the main cancer treatment, usually surgery. After neoadjuvant therapy shrinks the tumour or reduces local spread, surgery is performed to remove the remaining cancer. The goal is to achieve clear surgical margins, meaning no cancer cells are left at the edges of the removed tissue. This increases the chance of a cure and lowers the risk of recurrence. The type of surgery varies depending on the cancer location, type, and how well it responds to the neoadjuvant treatment.

Preparation Before Surgery

Preparation begins with a detailed evaluation. Imaging (MRI, CT, or ultrasound) is repeated to assess the tumour’s current size and location. Blood tests, cardiac clearance, and other organ function assessments are also conducted. Patients are advised to stop certain medications (like blood thinners) and follow specific diet instructions. Bowel preparation may be needed for rectal cancer surgeries. Counselling is provided to inform patients about surgical steps, possible outcomes, and recovery expectations.

What is the duration of neoadjuvant therapy?- Neoadjuvant Therapy in India

Breast Cancer: Lumpectomy or mastectomy – usually takes 1–3 hours
Rectal Cancer: Low anterior resection or abdominoperineal resection – 3–6 hours
Bladder Cancer: Radical cystectomy – 4–6 hours
Lung Cancer: Lobectomy or pneumonectomy – 2–4 hours

Recovery Time After Neoadjuvant Therapy

Recovery time after surgery depends on the type of cancer, the extent of surgery, and the patient’s overall health. Generally, hospital stays range from 2 to 7 days. For less invasive surgeries like breast lumpectomy, recovery may take 2 to 3 weeks, while more extensive procedures, such as rectal or bladder surgery, may require 6 to 8 weeks. Lung surgery recovery usually falls between 4 to 6 weeks. Patients may experience fatigue, mild pain, or wound discomfort, which gradually improve with rest and care. Early walking and light activity are encouraged to promote healing, and full recovery may take several months in complex cases.

Post-Surgical Care and Next Steps

Wound care, pain management, and gradual return to normal activity are part of recovery. Pathology results from the removed tumour determine if further adjuvant therapy (chemotherapy, radiation, or hormone therapy) is needed. Follow-up visits are scheduled to monitor healing and detect any recurrence early. Emotional and psychological support is also essential, especially if major organs were removed.

Neoadjuvant Therapy in India Price

Neoadjuvant therapy in India is widely available at leading cancer hospitals and is tailored to each patient based on cancer type, stage, and overall health. The treatment typically includes chemotherapy, radiation, or targeted therapies, and is supervised by a multidisciplinary team. Costs vary depending on the hospital, medications used, and duration of treatment.

Book Appointment

Get a free quote

Government hospitals and schemes offer subsidised options, while private centres provide advanced facilities and quicker access. Patients also have access to financial aid, insurance coverage, and support programs. With growing expertise and infrastructure, India offers high-quality neoadjuvant therapy comparable to international standards across major cities.

Cancer Type	Type of Neoadjuvant Therapy	Estimated Cost (INR)
Breast Cancer	Chemotherapy + Targeted Therapy	₹1,50,000 – ₹4,50,000
Rectal Cancer	Chemoradiotherapy	₹1,00,000 – ₹2,50,000
Lung Cancer	Chemotherapy	₹1,20,000 – ₹3,00,000
Bladder Cancer	Cisplatin-based Chemotherapy	₹1,00,000 – ₹2,50,000
Esophageal Cancer	Chemoradiotherapy	₹1,50,000 – ₹3,00,000
Pancreatic Cancer	Chemotherapy + Radiation (if used)	₹2,00,000 – ₹4,50,000
Cervical Cancer	Chemoradiotherapy	₹90,000 – ₹2,00,000
Ovarian Cancer	Neoadjuvant Chemotherapy	₹1,20,000 – ₹3,00,000

Best Hospitals For Neoadjuvant Therapy in India

Neoadjuvant therapy in India is provided by several top-tier cancer centres equipped with advanced technology and experienced oncology teams. These hospitals offer personalised treatment plans based on cancer type, stage, and patient health. Multidisciplinary teams, including medical, surgical, and radiation oncologists, work together to deliver chemotherapy, radiation, or targeted therapy before surgery.

Book Appointment

Get a free quote

The focus is on reducing tumour size, improving surgical outcomes, and increasing long-term survival. Patients receive continuous monitoring, pre-surgical assessments, and supportive care throughout the treatment. With well-organised systems and evidence-based protocols, these centres ensure safe, effective neoadjuvant therapy for various cancers, including breast, rectal, and bladder.

Location	Type
Tata Memorial Hospital	Mumbai, Maharashtra
All India Institute of Medical Sciences (AIIMS)	New Delhi
Adyar Cancer Institute	Chennai, Tamil Nadu
Rajiv Gandhi Cancer Institute & Research Centre	Delhi
Apollo Cancer Centre	Chennai, Delhi, Hyderabad
HCG Cancer Centre	Bengaluru, Karnataka
Max Super Speciality Hospital	Delhi, NCR
Fortis Memorial Research Institute	Gurugram, Haryana
Kokilaben Dhirubhai Ambani Hospital	Mumbai, Maharashtra
Christian Medical College (CMC)	Vellore, Tamil Nadu

We Care Health Services For Neoadjuvant Therapy

We Care Health Services offers expert guidance for neoadjuvant therapy across India’s top hospitals. They connect patients with leading oncologists, ensure personalized treatment plans, and assist with travel, appointments, and care coordination for a smooth and effective cancer treatment journey.

Access to top hospitals and oncologists
Personalised treatment coordination
Assistance with travel and accommodation
Support throughout therapy and recovery
Multilingual patient support and second opinions
High success rate for different surgeries
24*7 emergency support

Frequently Asked Questions:

1What is an example of neoadjuvant therapy?

An example of neoadjuvant therapy is chemotherapy given before surgery in breast cancer to shrink the tumour. This approach can make breast-conserving surgery possible and helps doctors assess how the cancer responds to treatment before removing it.

2How many cycles of neoadjuvant chemotherapy for bladder cancer?

Neoadjuvant chemotherapy for bladder cancer typically involves 3 to 4 cycles over 9 to 12 weeks. The exact number depends on the patient’s health, cancer stage, and response to treatment. Common regimens include cisplatin-based combinations like MVAC or Gem-Cis.

3What is the success rate of neoadjuvant chemotherapy?

The success rate of neoadjuvant chemotherapy varies by cancer type but often leads to tumour shrinkage in 30–60% of cases. In some, it achieves pathologic complete response, improving survival rates and making surgery more effective and less extensive.

4What are the risks of neoadjuvant therapy?

Neoadjuvant therapy can cause several risks, including fatigue, nausea, vomiting, hair loss, and lowered immunity due to chemotherapy. Radiation may lead to skin irritation, bowel or bladder issues, and localised pain. There's also a risk of poor response, delaying surgery. Some patients may experience weight loss or organ toxicity. Careful monitoring is essential to manage side effects and ensure the treatment is effective before proceeding to surgery.